Insulet Company Insiders

PODD Stock  USD 164.42  1.83  1.10%   
About 80 percent of Insulet's insiders are selling. The analysis of insiders' sentiment of trading Insulet stock suggests that quite a large number of insiders are terrified at this time. Insulet employs about 3 K people. The company is managed by 37 executives with a total tenure of roughly 240 years, averaging almost 6.0 years of service per executive, having 81.08 employees per reported executive.
Patrick Sullivan  CEO
CEO and President and Director
James Hollingshead  CEO
CEO President

Insulet's Insider Buying Vs Selling

20

 
Selling
 
Buying

Latest Trades

2024-02-28Shacey PetrovicDisposed 11609 @ 162.92View
2023-12-22Markwayne MullinDisposed @ 216.18
2023-11-13Shacey PetrovicDisposed 20000 @ 164.33View
2023-09-19Prem SinghAcquired 1 @ 168.92View
2023-08-28James HollingsheadAcquired 5550 @ 181.41View
2023-07-12Daniel S. GoldmanDisposed @ 285.49
2023-07-03Wayde D McmillanDisposed 1388 @ 282.94View
2023-06-20Dan ManeaDisposed 175 @ 290View
2023-06-05Luciana BorioDisposed 500 @ 283.38View
2023-06-01Shacey PetrovicDisposed 15000 @ 271.56View
Monitoring Insulet's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.

Acquired vs Disposed

Filed vs Not Filed

Insider sentiment refers to the collective sentiment or feeling of Insulet's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Insulet. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Insulet's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Insulet. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Insulet Stock refer to our How to Trade Insulet Stock guide.

Insulet's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Insulet's future performance. Based on our forecasts, it is anticipated that Insulet will maintain a workforce of about 3000 employees by May 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Insulet's latest congressional trading

Congressional trading in companies like Insulet, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Insulet by those in governmental positions are based on the same information available to the general public.
2024-04-04Senator Tina SmithAcquired $50K to $100KVerify
2023-12-22Senator Markwayne MullinAcquired Under $15KVerify
2023-07-12Representative Daniel GoldmanDisposed Under $15KVerify
2021-02-16Representative Peter MeijerDisposed $15K to $50KVerify

Insulet Management Team Effectiveness

The company has return on total asset (ROA) of 0.0609 % which means that it generated a profit of $0.0609 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3413 %, meaning that it created $0.3413 on every $100 dollars invested by stockholders. Insulet's management efficiency ratios could be used to measure how well Insulet manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.09. The current year's Return On Capital Employed is expected to grow to 0.11. At present, Insulet's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 1.1 B, whereas Intangibles To Total Assets are forecasted to decline to 0.06.
The current year's Net Income Applicable To Common Shares is expected to grow to about 5.6 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 44.7 M.

Insulet Workforce Comparison

Insulet is regarded second in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 9,890. Insulet totals roughly 3,000 in number of employees claiming about 30% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.12 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.26 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.26.

Insulet Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Insulet insiders, such as employees or executives, is commonly permitted as long as it does not rely on Insulet's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Insulet insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-03-01
1.0435
24
23
 124,841 
 28,401 
2023-12-01
0.2857
2
7
 20,000 
 66,202 
2023-09-01
0.4444
4
9
 15,010 
 20,346 
2023-06-01
1.5
9
6
 10,044 
 21,160 
2023-03-01
0.5424
32
59
 159,898 
 157,561 
2022-12-01
0.4615
6
13
 48,778 
 95,456 
2022-09-01
0.4
2
5
 15,000 
 40,830 
2022-06-01
1.2857
9
7
 43,561 
 25,316 
2022-03-01
0.9167
33
36
 200,108 
 117,308 
2021-12-01
0.4375
7
16
 29,333 
 57,661 
2021-09-01
0.3333
3
9
 36,596 
 100,232 
2021-06-01
0.9231
12
13
 53,191 
 82,127 
2021-03-01
0.8571
24
28
 126,984 
 66,373 
2020-12-01
0.6154
8
13
 48,710 
 92,937 
2020-09-01
0.25
2
8
 8,392 
 129,944 
2020-06-01
1.4286
10
7
 12,921 
 9,098 
2020-03-01
0.9565
22
23
 141,163 
 85,580 
2019-12-01
0.5
6
12
 23,606 
 40,390 
2019-09-01
0.3333
1
3
 2,033 
 4,802 
2019-06-01
1.1053
21
19
 78,797 
 97,840 
2019-03-01
0.5294
27
51
 190,536 
 207,396 
2018-12-01
0.375
3
8
 12,947 
 23,825 
2018-06-01
0.6364
14
22
 42,738 
 85,028 
2018-03-01
0.64
32
50
 443,529 
 147,848 
2017-12-01
1.0
1
1
 2,500 
 1,967 
2017-09-01
2.0
6
3
 67,123 
 2,434 
2017-06-01
6.3333
19
3
 77,707 
 2,595 
2017-03-01
1.3
26
20
 335,781 
 174,818 
2016-12-01
4.0
4
1
 52,775 
 3,075 
2016-06-01
2.5714
18
7
 112,946 
 17,907 
2016-03-01
2.3636
26
11
 639,000 
 81,801 
2015-09-01
1.0
3
3
 14,081 
 29,581 
2015-06-01
2.0909
23
11
 211,450 
 40,675 
2015-03-01
1.1875
19
16
 1,005,711 
 52,117 
2014-12-01
0.625
10
16
 1,075,848 
 71,500 
2014-09-01
0.4211
8
19
 73,751 
 173,500 
2014-06-01
1.0556
19
18
 139,750 
 216,108 
2014-03-01
0.8649
32
37
 530,217 
 494,410 
2013-12-01
0.4375
14
32
 196,811 
 440,978 
2013-09-01
0.4
4
10
 90,000 
 194,000 
2013-06-01
1.1429
24
21
 179,647 
 270,323 
2013-03-01
1.5
12
8
 274,200 
 125,877 
2012-12-01
0.4615
6
13
 100,836 
 165,155 
2012-09-01
0.5909
13
22
 153,000 
 206,000 
2012-06-01
1.5417
37
24
 661,298 
 316,416 
2012-03-01
0.325
13
40
 111,339 
 869,947 
2011-12-01
0.5
8
16
 69,500 
 103,299 
2011-09-01
0.6154
8
13
 63,200 
 121,900 
2011-06-01
1.1
22
20
 176,196 
 270,392 
2011-03-01
0.8788
29
33
 752,789 
 409,403 
2010-12-01
0.5
1
2
 1,500 
 3,000 
2010-09-01
0.5
5
10
 12,000 
 24,000 
2010-06-01
1.0
14
14
 37,500 
 27,000 
2010-03-01
0.7273
16
22
 158,917 
 185,417 
2009-12-01
0.3846
5
13
 10,500 
 38,080 
2009-09-01
1.3333
4
3
 37,480 
 12,246 
2009-06-01
1.0
3
3
 1,130 
 1,130 
2009-03-01
3.25
13
4
 505,000 
 25,000 
2008-12-01
3.0
18
6
 43,151 
 15,733 
2008-09-01
0.5714
4
7
 44,500 
 9,000 
2008-06-01
1.0
7
7
 25,450 
 9,000 
2008-03-01
0.2376
24
101
 516,823 
 402,307 
2007-12-01
0.6667
2
3
 38,500 
 514,052 
2007-09-01
1.0
1
1
 130,000 
 0.00 
2007-06-01
0.5672
38
67
 27,125,367 
 47,226,066 

Insulet Notable Stakeholders

An Insulet stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Insulet often face trade-offs trying to please all of them. Insulet's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Insulet's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Patrick SullivanCEO and President and DirectorProfile
James HollingsheadCEO PresidentProfile
Eric BenjaminSenior Vice President R&D, New Product Development and CommercializationProfile
Deborah GordonVice President Investor Relations and Corporate CommunicationsProfile
John KapplesSenior Vice President General Counsel, SecretaryProfile
Wayde McMillanCFO, Executive Vice PresidentProfile
Charles AlpucheSenior Vice President Global Manufacturing and OperationsProfile
David ColleranVice President General CounselProfile
Brittany BradrickVice President - Strategy and Corporate DevelopmentProfile
Aiman AbdelMalekSenior Vice President Advanced Technology and EngineeringProfile
Mark LicariVice President - Global Manufacturing and OperationsProfile
Michael SpearsSenior Vice President Quality, Regulatory, and Clinical AffairsProfile
Trang LyVice President and Medical DirectorProfile
Michael LevitzCFOProfile
Mark FieldSenior CTOProfile
Bradley ThomasExecutive VP of HR and Organizational Devel.Profile
Sally CrawfordLead Independent DirectorProfile
John FallonIndependent DirectorProfile
Daniel LevangieIndependent DirectorProfile
James MullenIndependent DirectorProfile
Charles LiamosDirector of Advanced Technology and DirectorProfile
David LemoineIndependent DirectorProfile
Jessica HopfieldDirectorProfile
Timothy ScannellDirectorProfile
Michael MinogueIndependent DirectorProfile
Steven SobieskiIndependent DirectorProfile
Corinne NevinnyIndependent DirectorProfile
Regina SommerIndependent DirectorProfile
Joseph ZakrzewskiIndependent DirectorProfile
Philip HildaleSenior CareProfile
Laetitia CousinQuality AffairsProfile
Bret ChristensenChief Commercial OfficerProfile
Deborah CPAVice RelationsProfile
Prem SinghSenior OperationsProfile
Angela WiczekSenior CommunicationsProfile
Lauren BuddenChief VPProfile
Shacey PetrovicChief Commercial OfficerProfile

About Insulet Management Performance

The success or failure of an entity such as Insulet often depends on how effective the management is. Insulet management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Insulet management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Insulet management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.08  0.09 
Return On Capital Employed 0.10  0.11 
Return On Assets 0.08  0.08 
Return On Equity 0.28  0.30 
The data published in Insulet's official financial statements usually reflect Insulet's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Insulet. For example, before you start analyzing numbers published by Insulet accountants, it's critical to develop an understanding of what Insulet's liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of Insulet's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Insulet's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Insulet's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Insulet. Please utilize our Beneish M Score to check the likelihood of Insulet's management manipulating its earnings.

Insulet Workforce Analysis

Traditionally, organizations such as Insulet use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Insulet within its industry.

Insulet Manpower Efficiency

Return on Insulet Manpower

Revenue Per Employee565.7K
Revenue Per Executive45.9M
Net Income Per Employee68.8K
Net Income Per Executive5.6M
Working Capital Per Employee377.2K
Working Capital Per Executive30.6M
When determining whether Insulet is a strong investment it is important to analyze Insulet's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Insulet's future performance. For an informed investment choice regarding Insulet Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Insulet. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
For information on how to trade Insulet Stock refer to our How to Trade Insulet Stock guide.
Note that the Insulet information on this page should be used as a complementary analysis to other Insulet's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Insulet Stock analysis

When running Insulet's price analysis, check to measure Insulet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insulet is operating at the current time. Most of Insulet's value examination focuses on studying past and present price action to predict the probability of Insulet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insulet's price. Additionally, you may evaluate how the addition of Insulet to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Is Insulet's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insulet. If investors know Insulet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insulet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
5.043
Earnings Share
2.94
Revenue Per Share
24.331
Quarterly Revenue Growth
0.379
Return On Assets
0.0609
The market value of Insulet is measured differently than its book value, which is the value of Insulet that is recorded on the company's balance sheet. Investors also form their own opinion of Insulet's value that differs from its market value or its book value, called intrinsic value, which is Insulet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insulet's market value can be influenced by many factors that don't directly affect Insulet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insulet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insulet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insulet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.